Skip to main content
Top
Published in: Medical Oncology 1/2011

01-12-2011 | Original Paper

Protective effect of l-carnitine versus amifostine against cisplatin-induced nephrotoxicity in rats

Authors: Sernaz Uzunoglu, Hakan Karagol, Fulya Ozpuyan, Rusen Cosar, Irfan Cicin, Vuslat Yurutcaloglu, Bengü Denizli, Özgür Tanriverdi, Necdet Sut, Zafer Kocak

Published in: Medical Oncology | Special Issue 1/2011

Login to get access

Abstract

We aimed to compare the protective effect of l-carnitine (CAR) and amifostine (AMF) against cisplatin (CDDP)-induced nephrotoxicity through biochemical markers and histopathological evaluation. Fifty-seven Wistar albino male rats were randomly classified into six groups, which were AMF+CDDP (n = 11; 200 mg/kg AMF 30 min prior to 7 mg/kg CDDP), CAR+CDDP (n = 11; 300 mg/kg CAR 30 min prior to 7 mg/kg CDDP), CDDP (n = 11; 1 mL/kg isotonic saline 30 min prior to 7 mg/kg CDDP), AMF (n = 8; 200 mg/kg AMF alone), CAR (n = 8; 300 mg/kg CAR alone), and control (n = 8; 1 mL/kg isotonic saline alone). All drugs were given intraperitoneally. Five days after medication, animals were killed, and samples of blood and kidney tissues were collected for biochemical and histopathological evaluation. The serum urea level was highest in AMF+CDDP group among CDDP-applied groups without statistical significance (median, range: 88, 56–21 mg/dL; P > 0.05). There was no statistical significance among CDDP-applied groups in terms of creatinine level (P > 0.05). In the AMF+CDDP group, the median glomerular, tubular, and tubulointerstitial inflammatory damage scores were significantly higher than the other CDDP-applied groups (P < 0.001). The difference between CAR+CDDP and CDDP groups was not statistically significant in terms of renal damage scores. AMF+CDDP group had significantly higher median total nephrotoxicity score than all the other groups (P < 0.001). To conclude, AMF or CAR has no protective effect on CDDP-induced nephrotoxicity. Furthermore, our findings suggest that application of AMF before CDDP may enhance CDDP-induced nephrotoxicity histopathologically.
Literature
1.
go back to reference Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. Oncol Rep. 2003;10:1663–82.PubMed Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. Oncol Rep. 2003;10:1663–82.PubMed
2.
go back to reference Townsend DM, Deng M, Zuong L, Lapus MG, Harigan MH. Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol. 2003;14:1–10.PubMedCrossRef Townsend DM, Deng M, Zuong L, Lapus MG, Harigan MH. Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol. 2003;14:1–10.PubMedCrossRef
3.
go back to reference Seguro AC, Shimizu MH, Kudo LH, dos Santos Rocha A. Renal concentration defect induced by cisplatin. The role of thick ascending limb and papillary collecting duct. Am J Nephrol. 1989;9:59–65.PubMedCrossRef Seguro AC, Shimizu MH, Kudo LH, dos Santos Rocha A. Renal concentration defect induced by cisplatin. The role of thick ascending limb and papillary collecting duct. Am J Nephrol. 1989;9:59–65.PubMedCrossRef
4.
go back to reference Tokatlı F, et al. The potential cardioprotective effects of amifostine in irradiated rats. Int J Radiant Oncol Biol Phys. 2004;58:1228–34.CrossRef Tokatlı F, et al. The potential cardioprotective effects of amifostine in irradiated rats. Int J Radiant Oncol Biol Phys. 2004;58:1228–34.CrossRef
5.
go back to reference Uzal C, et al. The protective effect of amifostine on radiation-induced acute pulmonary toxicity: detection by 99-m Tc-DTPA transalveolar clearances. Int J Radiant Oncol Biol Phys. 2004;60:564–9. Uzal C, et al. The protective effect of amifostine on radiation-induced acute pulmonary toxicity: detection by 99-m Tc-DTPA transalveolar clearances. Int J Radiant Oncol Biol Phys. 2004;60:564–9.
6.
go back to reference Treskes M, Van der Vijgh WJ. WR-2721 as a modulator of cisplatin and carboplatin- induced side effects in comparison with other chemoprotective agents: a molecular approach. Cancer Chemother. Pharmacol. 1993;33:93–106. Treskes M, Van der Vijgh WJ. WR-2721 as a modulator of cisplatin and carboplatin- induced side effects in comparison with other chemoprotective agents: a molecular approach. Cancer Chemother. Pharmacol. 1993;33:93–106.
7.
go back to reference Treskes M, Nijtmans LG, Fichtinger-Chapmen AM, Van der Vijgh WJ. Effects of the modulating agent WR 2721 and its main metabolites on the formation and stability of cisplatin DNA adducts in vitro in comparison to the effect of thiosulfate and diethhylthiocarbamate. Biochem Parmacol. 1992;43:1013–9.CrossRef Treskes M, Nijtmans LG, Fichtinger-Chapmen AM, Van der Vijgh WJ. Effects of the modulating agent WR 2721 and its main metabolites on the formation and stability of cisplatin DNA adducts in vitro in comparison to the effect of thiosulfate and diethhylthiocarbamate. Biochem Parmacol. 1992;43:1013–9.CrossRef
8.
go back to reference Schuchter LM, Glick J. The current status of WR-2721 (amifostine): a chemotherapy and radiation therapy protector. Biol Ther Cancer. 1993;3:1–10. Schuchter LM, Glick J. The current status of WR-2721 (amifostine): a chemotherapy and radiation therapy protector. Biol Ther Cancer. 1993;3:1–10.
9.
go back to reference Hensley ML, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol. 2009;27:127–45.PubMedCrossRef Hensley ML, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol. 2009;27:127–45.PubMedCrossRef
10.
go back to reference Vanella A, et al. l-Propionyl-carnitine as superoxide scavenger, antioxidant, and DNA cleavage protector. Cell Biol Toxicol. 2000;16:99–104.PubMedCrossRef Vanella A, et al. l-Propionyl-carnitine as superoxide scavenger, antioxidant, and DNA cleavage protector. Cell Biol Toxicol. 2000;16:99–104.PubMedCrossRef
11.
go back to reference Chang B, Nishikavva M, Sato E, Utsumi K, Inoue M. l-Carnitine inhibits cisplatin-induced injury of the kidney and small intestine. Arch Biochem Biophys. 2002;405:55–64.PubMedCrossRef Chang B, Nishikavva M, Sato E, Utsumi K, Inoue M. l-Carnitine inhibits cisplatin-induced injury of the kidney and small intestine. Arch Biochem Biophys. 2002;405:55–64.PubMedCrossRef
12.
go back to reference Kopple JD, et al. l-Carnitine ameliorates gentamicin-induced renal injury in rats. Nephrol Dial Transplant. 2002;17:2122–31.PubMedCrossRef Kopple JD, et al. l-Carnitine ameliorates gentamicin-induced renal injury in rats. Nephrol Dial Transplant. 2002;17:2122–31.PubMedCrossRef
13.
go back to reference Boonsanit D, Kanchanapangka S, Buranakarl C. L Carnitine ameliorates doxorubicin-induced nephrotic syndrome in rats. Nephrology. 2006;11:313–20.PubMedCrossRef Boonsanit D, Kanchanapangka S, Buranakarl C. L Carnitine ameliorates doxorubicin-induced nephrotic syndrome in rats. Nephrology. 2006;11:313–20.PubMedCrossRef
14.
go back to reference Sener G, et al. l-Carnitine ameliorates oxidative damage due to chronic renal failure in rats. J Cardiovasc Pharmacol. 2004;43:698–705.PubMedCrossRef Sener G, et al. l-Carnitine ameliorates oxidative damage due to chronic renal failure in rats. J Cardiovasc Pharmacol. 2004;43:698–705.PubMedCrossRef
15.
go back to reference Caloglu M, et al. Histopathological and scintigraphic comparisons of the protective effects of l-carnitine and amifostine against radiation-induced late renal toxicity in rats. Clin Exp Pharmacol Physiol. 2009;36:523–30.PubMedCrossRef Caloglu M, et al. Histopathological and scintigraphic comparisons of the protective effects of l-carnitine and amifostine against radiation-induced late renal toxicity in rats. Clin Exp Pharmacol Physiol. 2009;36:523–30.PubMedCrossRef
16.
go back to reference CIOMS International Guiding Principles for Biomedical Research Involving Animals. Altern Lab Anim. 1985; 12:ii. CIOMS International Guiding Principles for Biomedical Research Involving Animals. Altern Lab Anim. 1985; 12:ii.
18.
go back to reference Ali BH, Al-Moundhri MS. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research. Food Chem Toxicol. 2006;44:1173–83.PubMedCrossRef Ali BH, Al-Moundhri MS. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research. Food Chem Toxicol. 2006;44:1173–83.PubMedCrossRef
19.
go back to reference Spencer CM, Goa KL. Amifostine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector. Drugs. 1995;50:1001–31.PubMedCrossRef Spencer CM, Goa KL. Amifostine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector. Drugs. 1995;50:1001–31.PubMedCrossRef
20.
go back to reference Santini V, Giles FJ. The potential of amifostine: from cytoprotectant to therapeutic agent. Haematologica. 1999;84:1035–42.PubMed Santini V, Giles FJ. The potential of amifostine: from cytoprotectant to therapeutic agent. Haematologica. 1999;84:1035–42.PubMed
21.
go back to reference Santini V. Amifostine: chemotherapeutic and radiotherapeutic protective effects. Exp Opin Pharmocother. 2001;2:479–89.CrossRef Santini V. Amifostine: chemotherapeutic and radiotherapeutic protective effects. Exp Opin Pharmocother. 2001;2:479–89.CrossRef
22.
go back to reference Foster-Nora JA, Siden R. Amifostine for protection from antineoplastic drug toxicity. Am J Health Syst Pharm. 1997;54:787–800.PubMed Foster-Nora JA, Siden R. Amifostine for protection from antineoplastic drug toxicity. Am J Health Syst Pharm. 1997;54:787–800.PubMed
23.
go back to reference Calvani M, et al. Carnitine replacement in end-stage renal disease and hemodialysis. Ann N Y Acad Sci. 2004;1033:52–66.PubMedCrossRef Calvani M, et al. Carnitine replacement in end-stage renal disease and hemodialysis. Ann N Y Acad Sci. 2004;1033:52–66.PubMedCrossRef
24.
go back to reference Pisano C, et al. Paclitaxel and cisplatin- induced neurotoxicity. A protective role of acetyl-l-Carnitine. Clin Cancer Res. 2003;9:5756–67.PubMed Pisano C, et al. Paclitaxel and cisplatin- induced neurotoxicity. A protective role of acetyl-l-Carnitine. Clin Cancer Res. 2003;9:5756–67.PubMed
25.
go back to reference Aydogdu N, et al. Protective effects of l-Carnitine on myoglobinuric acute renal failure in rats. Clin Exp Pharmacol Physiol. 2006;33:119–24.PubMedCrossRef Aydogdu N, et al. Protective effects of l-Carnitine on myoglobinuric acute renal failure in rats. Clin Exp Pharmacol Physiol. 2006;33:119–24.PubMedCrossRef
26.
go back to reference Aleisa AM, et al. Reversal of cisplatin-induced carnitine deficiency and energy starvation by propionyl-l-Carnitine in rat kidney tissues. Clin Exp Pharmacol Physiol. 2007;34:1252–9.PubMedCrossRef Aleisa AM, et al. Reversal of cisplatin-induced carnitine deficiency and energy starvation by propionyl-l-Carnitine in rat kidney tissues. Clin Exp Pharmacol Physiol. 2007;34:1252–9.PubMedCrossRef
27.
go back to reference Srivastava RC, et al. Evidence for the involvement of nitric oxide in cisplatin-induced toxicity in rats. Biometals. 1996;9:139–42.PubMedCrossRef Srivastava RC, et al. Evidence for the involvement of nitric oxide in cisplatin-induced toxicity in rats. Biometals. 1996;9:139–42.PubMedCrossRef
28.
go back to reference Sayad-Ahmed MM, et al. Progression of cisplatin-induced nephrotoxicity in a carnitine-depleted rat model. Chemotherapy. 2004;50:162–70.CrossRef Sayad-Ahmed MM, et al. Progression of cisplatin-induced nephrotoxicity in a carnitine-depleted rat model. Chemotherapy. 2004;50:162–70.CrossRef
29.
go back to reference Ward JM, Fauvie KA. The nephrotoxic effect of cis-dichlorodiamine-platinum in male F344 rats. Toxicol Appl Pharmacol. 1976;38:535–47.PubMedCrossRef Ward JM, Fauvie KA. The nephrotoxic effect of cis-dichlorodiamine-platinum in male F344 rats. Toxicol Appl Pharmacol. 1976;38:535–47.PubMedCrossRef
30.
go back to reference Shimeda Y, et al. Protective effects of capsaicin against cisplatin nephrotoxicity in rats. Biol Pharm Bull. 2005;28:1635–8.PubMedCrossRef Shimeda Y, et al. Protective effects of capsaicin against cisplatin nephrotoxicity in rats. Biol Pharm Bull. 2005;28:1635–8.PubMedCrossRef
31.
go back to reference Karimi G, Ramezani M, Tahoonian Z. Cisplatin nephrotoxicity and protection by milk thistle extract in rats. Evid Based Complement Alternat Med. 2005;2:383–6.PubMedCrossRef Karimi G, Ramezani M, Tahoonian Z. Cisplatin nephrotoxicity and protection by milk thistle extract in rats. Evid Based Complement Alternat Med. 2005;2:383–6.PubMedCrossRef
32.
go back to reference Dickey TD, Wu J, Muldoon LL, Neuwelt EA. Protection against cisplatin-induced toxicities by N-Acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular and in vivo levels. J Pharmacol Exp Ther. 2005;314:1052–8.PubMedCrossRef Dickey TD, Wu J, Muldoon LL, Neuwelt EA. Protection against cisplatin-induced toxicities by N-Acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular and in vivo levels. J Pharmacol Exp Ther. 2005;314:1052–8.PubMedCrossRef
33.
go back to reference Petrilli AS, et al. Use of amifostine in the therapy of osteosarcoma in children and adolescents. J Pediatr Hematol Oncol. 2002;24:188–91.PubMedCrossRef Petrilli AS, et al. Use of amifostine in the therapy of osteosarcoma in children and adolescents. J Pediatr Hematol Oncol. 2002;24:188–91.PubMedCrossRef
34.
go back to reference Sastry J, Kellie SJ. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr Hematol Oncol. 2005;22:441–5.PubMedCrossRef Sastry J, Kellie SJ. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr Hematol Oncol. 2005;22:441–5.PubMedCrossRef
Metadata
Title
Protective effect of l-carnitine versus amifostine against cisplatin-induced nephrotoxicity in rats
Authors
Sernaz Uzunoglu
Hakan Karagol
Fulya Ozpuyan
Rusen Cosar
Irfan Cicin
Vuslat Yurutcaloglu
Bengü Denizli
Özgür Tanriverdi
Necdet Sut
Zafer Kocak
Publication date
01-12-2011
Publisher
Springer US
Published in
Medical Oncology / Issue Special Issue 1/2011
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9746-2

Other articles of this Special Issue 1/2011

Medical Oncology 1/2011 Go to the issue